Caliway Biopharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Caliway Biopharmaceuticals's earnings have been declining at an average annual rate of -33.8%, while the Pharmaceuticals industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 62.6% per year.
Key information
-33.8%
Earnings growth rate
-22.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 62.6% |
| Return on equity | -13.1% |
| Net Margin | -1,254.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Caliway Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 39 | -488 | 37 | 504 |
| 30 Sep 23 | 33 | -459 | 35 | 480 |
| 30 Jun 23 | 28 | -429 | 32 | 455 |
| 31 Mar 23 | 20 | -358 | 33 | 375 |
| 31 Dec 22 | 13 | -286 | 34 | 295 |
| 30 Sep 22 | 6 | -275 | 49 | 255 |
| 30 Jun 22 | 0 | -263 | 63 | 215 |
| 31 Mar 22 | 6 | -244 | 61 | 198 |
| 31 Dec 21 | 12 | -224 | 59 | 181 |
| 31 Dec 20 | 10 | -98 | 23 | 89 |
| 31 Dec 19 | 19 | -122 | 24 | 109 |
Quality Earnings: 6919 is currently unprofitable.
Growing Profit Margin: 6919 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6919 is unprofitable, and losses have increased over the past 5 years at a rate of 33.8% per year.
Accelerating Growth: Unable to compare 6919's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6919 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-15%).
Return on Equity
High ROE: 6919 has a negative Return on Equity (-13.06%), as it is currently unprofitable.